Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis.

ABSTRACT:

Introduction

Sodium-glucose cotransporter 2 (SGLT2) is expressed in the human peritoneum, and preclinical studies suggest that SGLT2 inhibitors may enhance ultrafiltration by reducing glucose absorption from peritoneal dialysis (PD) solutions. This study evaluated whether empagliflozin increases ultrafiltration volume (UFV) in patients on PD.

Methods

In this multicenter, randomized (1:1), double-blind, placebo-controlled crossover trial, patients on PD received empagliflozin (10 mg/d) or placebo for 8 weeks, separated by a 4-week washout period. The primary outcome was the change in daily UFV from baseline to week 8 in each treatment period.

Results

Of 40 randomized patients, 37 received treatment and were analyzed. The median age was 66 years, PD duration was 2.8 yea

SUBMITTER: Doi Y 

PROVIDER: S-EPMC12799575 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature